Scarica l'app Stockscreener
103.42
1.29%
-1.365
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$104.78
Aprire:
$104.73
Volume 24 ore:
3.11M
Relative Volume:
0.39
Capitalizzazione di mercato:
$147.06B
Reddito:
$17.55B
Utile/perdita netta:
$2.03B
Rapporto P/E:
75.49
EPS:
1.37
Flusso di cassa netto:
$2.72B
1 W Prestazione:
-0.82%
1M Prestazione:
-0.71%
6M Prestazione:
+15.72%
1 anno Prestazione:
+35.11%
Intervallo 1D:
$102.67
$105.39
Intervallo di 1 settimana:
$102.67
$107.53
Portata 52W:
$71.88
$107.53
Boston Scientific Corp Stock (BSX) Company Profile
Nome
Boston Scientific Corp
Settore
Industria
Telefono
508-683-4000
Indirizzo
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Confronta BSX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
103.41 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
ABT
Abbott Laboratories
|
134.30 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
SYK
Stryker Corp
|
391.00 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.57 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.85 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-16 | Iniziato | Leerink Partners | Outperform |
| 2025-04-16 | Aggiornamento | Needham | Hold → Buy |
| 2025-01-10 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-10-18 | Downgrade | Needham | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-02-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-07-19 | Iniziato | Robert W. Baird | Outperform |
| 2023-06-30 | Iniziato | CL King | Buy |
| 2023-05-30 | Ripresa | Morgan Stanley | Overweight |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-12-22 | Iniziato | Mizuho | Neutral |
| 2022-12-20 | Ripresa | Citigroup | Buy |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-06 | Iniziato | Wolfe Research | Outperform |
| 2022-05-27 | Aggiornamento | Needham | Hold → Buy |
| 2022-04-13 | Ripresa | Truist | Buy |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-05-26 | Downgrade | Needham | Buy → Hold |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-17 | Iniziato | Truist | Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Peer Perform |
| 2020-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-01 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Buy |
| 2019-12-30 | Reiterato | Cowen | Outperform |
| 2019-12-19 | Downgrade | Needham | Strong Buy → Buy |
| 2019-09-05 | Ripresa | JP Morgan | Overweight |
| 2019-09-03 | Ripresa | Barclays | Overweight |
| 2019-05-13 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-11-28 | Iniziato | UBS | Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-10-02 | Reiterato | Morgan Stanley | Overweight |
| 2018-09-07 | Reiterato | Needham | Strong Buy |
| 2018-09-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2018-07-06 | Reiterato | Needham | Strong Buy |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-04-26 | Reiterato | Needham | Strong Buy |
Mostra tutto
Boston Scientific Corp Borsa (BSX) Ultime notizie
February 2026 Options Now Available For Boston Scientific (BSX) - Nasdaq
Boston Scientific’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings - Investing.com Canada
This Boston Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Boston Scientific (BSX) Receives Outperform Rating from Leerink Partners | BSX Stock News - GuruFocus
Boston Scientific (BSX) Receives Outperform Rating from Analyst | BSX Stock News - GuruFocus
Does This Valuation Of Boston Scientific Corporation (NYSE:BSX) Imply Investors Are Overpaying? - Yahoo Finance
Why the Market Dipped But Boston Scientific (BSX) Gained Today - Yahoo Finance
Boston Scientific Shares Rally Over 1%, Highlighting Strong Long-Term Growth - Daily Chhattisgarh News
BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth? - Yahoo Finance
What's the secret behind Boston Sci's successful product launches? - BioWorld MedTech
Implantable Remote Patient Monitoring Devices Market to Grow 21.7% CAGR by 2029 - GlobeNewswire Inc.
Five things: The Newbury GM, Zoominfo cuts, Vertex, Boston Scientific and casino night - The Business Journals
Boston Scientific to sell 24-acre campus in Minnetonka - Finance & Commerce
Boston Scientific is selling a Minnesota campus - MassDevice
Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock - The Globe and Mail
Boston Scientific lists 24-acre Minnesota campus for sale ahead of Maple Grove move - The Business Journals
How Is Boston Scientific's Stock Performance Compared to Other Medical Device Stocks? - MSN
Boston Scientific lists 24-acre Minnetonka campus for sale ahead of Maple Grove move - The Business Journals
Boston Scientific Stock Slips Over 1% Amid Short-Term Pullback - Daily Chhattisgarh News
Boston Scientific (BSX) Upgraded to Buy: Here's Why - Yahoo Finance
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy? - Yahoo Finance
Boston Scientific’s EVP sells $5.8 million in stock By Investing.com - Investing.com Nigeria
Boston Scientific’s EVP sells $5.8 million in stock - Investing.com
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Boston Scientific (NYSE:BSX) Secures US$30-45 Million Deal with Bittium for ECG Devices - Yahoo Finance
Emerging Markets Power Boston Scientific: Will The Growth Trend Continue? - Barchart.com
Here's Why Boston Scientific (BSX) is a Strong Growth Stock - Yahoo Finance
Emerging Markets Power Boston Scientific: Will the Growth Trend Continue? - Yahoo Finance
How Is Boston Scientific's Stock Performance Compared To Other Medical Device Stocks? - Barchart.com
Rising obesity levels spur endoscopic sleeve uptick - BioWorld MedTech
Boston Scientific (BSX): Company Profile, Stock Price, News, Rankings - Fortune
Boston Scientific’s longtime DEI, HR leader exits for chief HR role at new company - MassDevice
Insider Sell: Edward Ludwig Sells 4,000 Shares of Boston Scienti - GuruFocus
Before the Bell-Boston Scientific drops on profit miss - Reuters
Insider Sell: Edward Ludwig Sells 4,000 Shares of Boston Scientific Corp (BSX) - GuruFocus
Piper Sandler maintains Boston Scientific stock at Overweight - Investing.com
Boston Scientific (NYSE:BSX) Receives “Buy” Rating from Needham & Company LLC - Defense World
Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook - Benzinga
Boston Scientific ends TAVR sales; J&J shares Monarch robot data - MedTech Dive
Boston Scientific (BSX) Ends Acurate TAVR Program, Shifts Focus to Promising Projects | BSX Stock News - GuruFocus
BSX: Analyst Reiterates Buy Rating for Boston Scientific | BSX S - GuruFocus
In TAVR setback, Boston Sci pulls plug on Acurate valves - BioWorld MedTech
Boston Scientific discontinues Acurate TAVR sales, cites regulatory burden - MassDevice
Boston Scientific Ends ACURATE Valve Sales By Investing.com - Investing.com Canada
Evercore ISI maintains Boston Scientific stock at Outperform - Investing.com
TD Cowen maintains Boston Scientific stock at $115 target By Investing.com - Investing.com South Africa
TD Cowen maintains Boston Scientific stock at $115 target - Investing.com
Boston Scientific (BSX) Discontinues Sales of ACURATE Aortic Valve Systems - GuruFocus
Boston Scientific (BSX) Discontinues Valve Product Amid Regulato - GuruFocus
Boston Scientific Corp Azioni (BSX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Boston Scientific Corp Azioni (BSX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology |
Jun 04 '25 |
Sale |
102.88 |
56,372 |
5,799,630 |
178,342 |
1.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):